CJC-1295 (No DAC) Mechanism of Action (Receptor Targets Explained)

Structural Overview and Chemical Identity of CJC-1295 (No DAC)

CJC-1295 (No DAC)—frequently cataloged in scientific literature as Modified GRF 1-29—is a 29-amino-acid synthetic peptide derivative of human growth hormone-releasing hormone (GHRH 1-29). Native GHRH 1-29 contains the full biological activity of the naturally occurring 44-amino-acid hypothalamic hormone, but it suffers from rapid enzymatic degradation in plasma, primarily via dipeptidyl peptidase IV (DPP-IV) cleavage at the Tyr1-Ala2 N-terminus.

To overcome this metabolic vulnerability in experimental settings, researchers engineered CJC-1295 (No DAC) with four targeted amino acid substitutions: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. The D-alanine substitution at position 2 provides robust resistance to DPP-IV enzymatic cleavage, while the remaining substitutions preserve alpha-helical structural integrity and enhance oxidative stability. Researchers investigating peptide structure-activity relationships can explore our complete all peptides catalog for complementary GHRH derivatives and reference standards.

Unlike the Drug Affinity Complex (DAC) variant—which incorporates a maleimidopropionic acid linker that covalently binds to circulating serum albumin—CJC-1295 (No DAC) lacks this albumin-binding motif. Consequently, it exhibits a distinct pharmacokinetic profile characterized by rapid cellular uptake and clearance without permanent plasma protein binding, making it an ideal candidate for controlled, short-duration bioassays.

Primary Target Engagement: GHRH Receptor Signaling

The primary mechanism of action for CJC-1295 (No DAC) centers on its selective agonism of the growth hormone-releasing hormone receptor (GHRHR). GHRHR belongs to the Secretin-like (Class B1) family of seven-transmembrane G protein-coupled receptors (GPCRs), expressed predominantly on the plasma membrane of anterior pituitary somatotroph cells in animal models.

Upon ligand binding, CJC-1295 (No DAC) induces a conformational shift in the GHRHR extracellular domain and transmembrane helices. Preclinical binding studies demonstrate that the tetrasubstituted peptide retains high nanomolar affinity for the receptor, comparable to or exceeding native GHRH 1-29, while demonstrating substantially prolonged receptor occupancy due to its resistance to local enzymatic degradation.

Intracellular Cascade: cAMP, PKA, and Transcriptional Pathways

Receptor engagement by CJC-1295 (No DAC) triggers the activation of the heterotrimeric G-protein subunit Gαs, which directly stimulates membrane-bound adenylate cyclase (AC). Activation of AC catalyzes the intracellular conversion of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), generating a sharp elevation in second-messenger levels.

Elevated intracellular cAMP binds to the regulatory subunits of Protein Kinase A (PKA), releasing active catalytic subunits. PKA subsequently translocates to the nucleus, where it phosphorylates the cAMP response element-binding protein (CREB). Phosphorylated CREB binds to specific promoter regions to upregulate transcription of the growth hormone (*GH1*) gene, promoting both de novo synthesis and vesicular storage of growth hormone within somatotrophs.

Simultaneously, intracellular signaling branches into the phospholipase C (PLC) / inositol trisphosphate (IP3) pathway, which triggers influx of extracellular calcium (Ca2+) through L-type voltage-gated calcium channels. This acute intracellular calcium spike facilitates the exocytosis of pre-stored secretory vesicles containing growth hormone into the extracellular space.

Downstream Endocrine Dynamics: Sustained GH and IGF-1 Secretion

In animal models, CJC-1295 (No DAC) functions as a powerful stimulator of pulsatile growth hormone secretion. By engaging GHRHR without forming irreversible systemic albumin complexes, it amplifies natural pulse amplitudes while preserving the physiological feedback mechanisms governed by hypothalamic somatostatin (SRIF).

The elevated release of growth hormone acts upon peripheral target tissues, primarily hepatic tissue, where GH binds to dimeric growth hormone receptors (GHR) to activate the JAK2/STAT5b signaling pathway. This hepatic signaling drives the transcription and systemic secretion of Insulin-like Growth Factor 1 (IGF-1) alongside its principal binding protein, IGFBP-3.

Because CJC-1295 (No DAC) is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, investigators routinely track plasma IGF-1 concentrations as a primary downstream biomarker of receptor target engagement. To review structural specifications or order analytical-grade material for your laboratory, visit the CJC-1295 (No DAC) product page.

Comparative Analysis: GHRH Analogs and Secretagogues

To evaluate secretagogue dynamics in vitro or in vivo, researchers frequently contrast GHRH analogs with distinct structural properties or alternative receptor pathways. Understanding these operational differences enables precise compound selection for cellular assays and metabolic models.

When comparing CJC-1295 (No DAC) against related research compounds such as Sermorelin and ghrelin receptor agonists like Ipamorelin, several functional distinctions emerge:

1. **CJC-1295 (No DAC) vs. Sermorelin**: Sermorelin represents the un-substituted 1-29 amino acid sequence of native GHRH. While both target GHRHR, Sermorelin remains vulnerable to DPP-IV cleavage, resulting in an in vivo half-life of approximately 8–12 minutes. The tetrasubstituted design of CJC-1295 (No DAC) extends half-life up to 30 minutes in rodent models without altering receptor specificity. 2. **CJC-1295 (No DAC) vs. CJC-1295 (with DAC)**: The DAC addition enables covalent conjugation to serum albumin, extending systemic circulation to several days. This leads to continuous, non-pulsatile GHRH receptor stimulation. Conversely, CJC-1295 (No DAC) permits episodic, pulsatile receptor activation, making it preferable for studies investigating normal physiological secretion patterns. 3. **CJC-1295 (No DAC) vs. Growth Hormone Secretagogue Receptor (GHSR) Agonists**: While CJC-1295 (No DAC) signals through the GHRHR-cAMP-PKA pathway, compounds like Ipamorelin or GHRP-6 target the ghrelin receptor (GHSR-1a) via phospholipase C and intracellular calcium release. Co-administration of GHRH analogs and GHSR agonists in preclinical research frequently demonstrates synergistic GH release, reflecting dual-pathway somatotroph activation.

Applications in Tissue Repair and Cellular Metabolism Research

In preclinical model systems, the sustained elevation of GH and IGF-1 driven by CJC-1295 (No DAC) has made it a focal point of tissue repair research. IGF-1 acts as a primary mitogenic driver in musculoskeletal, cutaneous, and connective tissue assays.

In vitro studies using tendon fibroblasts, osteoblasts, and skeletal myoblasts demonstrate that GHRH-mediated IGF-1 activation increases collagen type I and III synthesis, accelerates cellular proliferation, and promotes nitrogen retention. In animal models of wound healing, sustained somatotropic axis activity correlates with accelerated re-epithelialization and enhanced tensile strength of repairing extracellular matrices. Laboratories seeking to integrate these methodologies into broader research programs can explore institutional capabilities via our wholesale lab account portal.

What This Means for Assay Design

Integrating CJC-1295 (No DAC) into quantitative cell culture or animal assays requires careful timing and experimental controls. Because the compound induces rapid receptor activation followed by natural internalizing recycling of GHRHR, assay design must account for signal saturation and refractory periods.

For *in vitro* somatotroph cell cultures, maximal cAMP accumulation is typically observed within 15–30 minutes of administration, whereas measurable downstream protein output (such as GH accumulation in supernatant) peaks between 2 and 6 hours post-treatment. In rodent models, serum GH spikes rapidly within 15 to 45 minutes, while hepatic IGF-1 response exhibits a broader, sustained plateau extending from 6 to 24 hours.

Researchers conducting longitudinal tissue repair assays should calibrate sampling intervals around these distinct kinetic phases. Measuring both early-stage intracellular cAMP/PKA activation and late-stage IGF-1 expression provides a comprehensive profile of target engagement across the entire somatotropic axis. Additional literature and trial frameworks are available in our research library hub.

Reconstitution, Stability, and Handling Protocols

CJC-1295 (No DAC) is supplied as a lyophilized white powder to ensure long-term peptide stability. For laboratory work, proper reconstitution protocols must be followed to maintain chemical integrity and prevent aggregation.

Lyophilized vials should be reconstituted using sterile bacteriostatic water or laboratory-grade phosphate-buffered saline (PBS), depending on the requirements of the downstream assay. During fluid addition, the diluent should be directed down the glass wall of the vial rather than sprayed directly onto the peptide cake. Gentle swirl agitation is recommended; vigorous vortexing must be avoided to prevent mechanical shear stress and denaturation.

To calculate exact volumetric concentrations and working stock dilutions for bioassays, researchers should utilize our interactive reconstitution calculator. Reconstituted solutions should be aliquoted to avoid repeated freeze-thaw cycles and stored at -20°C or -80°C for extended experimental series.

Analytical Quality Standards and Verification

Experimental reproducibility relies entirely on compound purity, chemical identity, and the absence of biological contaminants. PX1 Research subjects every production lot of CJC-1295 (No DAC) to rigorous quality assurance protocols in ISO 17025 accredited analytical laboratories.

Purity is quantitatively verified via High-Performance Liquid Chromatography (HPLC), ensuring a minimum purity standard of ≥98%. Chemical identity and exact molecular mass (3288.7 Da) are confirmed through Mass Spectrometry (MS). Furthermore, all lots undergo Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly controlled below standard laboratory thresholds.

Researchers can independently inspect lot-specific documentation, mass spectra, and chromatographic profiles at any time through our transparent COA database.